NasdaqGS - Delayed Quote USD

Innate Pharma S.A. (IPHA)

Compare
3.0200 +1.4800 (+96.10%)
At close: December 13 at 4:00:01 PM EST
3.0000 -0.02 (-0.66%)
After hours: 7:59:18 PM EST
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
51,901.0000
51,901.0000
49,580.0000
12,110.0000
56,155.0000
Cost of Revenue
--
--
--
--
3,042.0000
Gross Profit
--
--
--
--
53,791.0000
Operating Expense
64,570.0000
64,570.0000
66,005.0000
59,937.0000
55,076.0000
Operating Income
-12,669.0000
-12,669.0000
-16,425.0000
-47,827.0000
1,079.0000
Net Non Operating Interest Income Expense
2,537.0000
2,537.0000
258.0000
15.0000
223.0000
Other Income Expense
2,562.0000
2,562.0000
-41,805.0000
2,330.0000
-2,131.0000
Pretax Income
-7,570.0000
-7,570.0000
-57,972.0000
-45,478.0000
-829.0000
Net Income Common Stockholders
-7,570.0000
-7,570.0000
-58,103.0000
-52,809.0000
-63,984.0000
Diluted NI Available to Com Stockholders
-7,570.0000
-7,570.0000
-58,103.0000
-52,809.0000
-63,984.0000
Basic EPS
-0.09
-0.09
-0.73
-0.66
-0.81
Diluted EPS
-0.09
-0.09
-0.73
-0.66
-0.81
Basic Average Shares
80,453.2820
84,111.1110
79,639.8260
79,542.6270
78,934.9600
Diluted Average Shares
80,453.2820
84,111.1110
79,639.8260
79,542.6270
78,934.9600
Total Operating Income as Reported
-12,669.0000
-12,669.0000
-57,425.0000
-47,825.0000
1,079.0000
Rent Expense Supplemental
--
--
--
--
1,702.0000
Total Expenses
64,570.0000
64,570.0000
66,005.0000
59,937.0000
55,076.0000
Net Income from Continuing & Discontinued Operation
-7,570.0000
-7,570.0000
-58,103.0000
-52,809.0000
-63,984.0000
Normalized Income
-10,132.0000
-10,132.0000
-16,167.0000
-47,808.0000
1,302.0000
Interest Income
3,177.0000
3,177.0000
546.0000
327.0000
564.0000
Interest Expense
640.0000
640.0000
288.0000
312.0000
341.0000
Net Interest Income
2,537.0000
2,537.0000
258.0000
15.0000
223.0000
EBIT
-6,930.0000
-6,930.0000
-57,684.0000
-45,166.0000
-488.0000
EBITDA
-1,839.0000
-1,839.0000
-12,279.0000
-40,570.0000
56,309.0000
Reconciled Cost of Revenue
--
--
--
--
3,042.0000
Reconciled Depreciation
5,091.0000
5,091.0000
45,405.0000
4,596.0000
56,797.0000
Net Income from Continuing Operation Net Minority Interest
-7,570.0000
-7,570.0000
-57,972.0000
-45,478.0000
-829.0000
Total Unusual Items Excluding Goodwill
2,562.0000
2,562.0000
-41,805.0000
2,330.0000
-2,131.0000
Total Unusual Items
2,562.0000
2,562.0000
-41,805.0000
2,330.0000
-2,131.0000
Normalized EBITDA
-4,401.0000
-4,401.0000
29,526.0000
-42,900.0000
58,440.0000
12/31/2020 - 10/17/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PBM Psyence Biomedical Ltd.
1.8500
-9.31%
 
PCSA Processa Pharmaceuticals, Inc.
1.1100
-11.20%
 
DBVT DBV Technologies S.A.
3.5700
-7.03%
 
SLXN Silexion Therapeutics Corp
3.5200
+5.39%
 
TRVI Trevi Therapeutics, Inc.
4.1700
+15.83%
 
SONN Sonnet BioTherapeutics Holdings, Inc.
1.8100
+2.26%
 
PALI Palisade Bio, Inc.
1.7700
-25.00%
 
NBTX Nanobiotix S.A.
3.3300
+1.52%
 
ADCT ADC Therapeutics SA
1.8900
-4.55%
 
AFMD Affimed N.V.
2.1500
-1.38%